Technology, FinTech & BioTech
Investment, acquisition and growth opportunities in enterprise technology, financial technology and biotechnology businesses.
Discuss an opportunity ↗Projects, stages and capital
Project types
Enterprise software, cybersecurity, SaaS, digital platforms, payment technology, RegTech, diagnostics, biotechnology, life-science innovation and selected cross-border technology acquisitions.
Project lifecycle
Seed-to-growth opportunities where suitable, later-stage expansion, buyouts, acquisitions and refinancing.
Funding and transaction structures
Growth equity, venture or strategic capital, acquisition debt, private credit and joint ventures.
Potential counterparties
Growth funds, private investors, family offices, strategic acquirers, specialist debt providers and corporate partners.
FinTech & financial technology
Payments infrastructure, financial software, digital platforms, compliance technology and selected regulated financial-services businesses, with appropriate licensing and regulatory review.
BioTech & life sciences
Biotechnology platforms, diagnostics, research-led healthcare businesses, medical technology and pharmaceutical innovation, including specialist growth and strategic investment requirements.
Acquisitions & business growth
Profitable operating companies, buyouts, bolt-on acquisitions and specialist growth transactions, including strategic investors and asset-backed lending.
The transaction sizes and geographies shown are indicative of the types of opportunities Spoog considers, not published mandates, eligibility thresholds, committed financing or assurances of investor availability. Details are intentionally anonymised. All introductions are subject to suitability, verification, permissions and agreed terms.
Where technology capital is deployed
These are representative transaction considerations informed by the types of opportunities and counterparties we engage with. They are not public listings or claims of completed transactions.
FinTech and payments infrastructure
Relevant opportunities include payments technology, embedded finance, compliance software, cross-border platforms and financial infrastructure. Investor assessment will consider licensing, partner dependencies, customer concentration, transaction economics and regulatory perimeter.
Enterprise software and AI technology
For SaaS and software businesses, recurring revenue, retention, unit economics, product differentiation, cybersecurity and customer acquisition efficiency are often more informative than headline user numbers.
BioTech and scientific innovation
Biotechnology and diagnostics companies require specialist diligence covering scientific validation, intellectual property, clinical or regulatory milestones and the amount of capital needed to reach the next value inflection point.
Acquisitions and structured growth
We also consider acquisition funding and strategic buyouts where the buyer can demonstrate commercial rationale, management capability, credible security or cash flows and an achievable transaction timetable.
Seeking capital or partners for Technology, FinTech or BioTech?
Send us a high-level summary of the sector, country, project stage and approximate funding requirement. Please do not include confidential documentation in the initial enquiry.
Enquire with Spoog ↗ Investor or lender enquiry ↗Looking for operational AI automation instead?
Explore our separate service for designing, building and operating bespoke business workflows.
AI Services & Automation ↗